|
1
|
Yeoh AE, Tan D, Li CK, Hori H, Tse E and
Pui CH; Asian Oncology Summit, : 2013.Management of adult and
paediatric acute lymphoblastic leukaemia in Asia:
Resource-stratified guidelines from the Asian Oncology Summit 2013.
Lancet Oncol. 14:e508–e523. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Alvarnas JC, Brown PA, Aoun P, Ballen KK,
Bellam N, Blum W, Boyer MW, Carraway HE, Coccia PF, Coutre SE, et
al: Acute lymphoblastic leukemia. J Natl Compr Canc Netw.
10:858–914. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Esparza SD and Sakamoto KM: Topics in
pediatric leukemia-acute lymphoblastic leukemia. MedGenMed.
7:232005.PubMed/NCBI
|
|
4
|
Ma H, Sun H and Sun X: Survival
improvement by decade of patients aged 0–14 years with acute
lymphoblastic leukemia: A SEER analysis. Sci Rep. 4:42272014.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kenderian SS, Al-Kali A, Gangat N,
Letendre L, Hogan WJ, Litzow MR and Patnaik MM: Monosomal karyotype
in Philadelphia chromosome-negative acute lymphoblastic leukemia.
Blood Cancer J. 3:e1222013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Koharazawa H, Kanamori H, Sakai R,
Hashimoto C, Takemura S, Hattori M, Taguchi J, Fujimaki K, Tomita
N, Fujita H, et al: Long-term outcome of L86 and L97 protocols for
adult acute lymphoblastic leukemia. Leuk Lymphoma. 49:2133–2140.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Pulte D, Jansen L, Gondos A, Katalinic A,
Barnes B, Ressing M, Holleczek B, Eberle A and Brenner H: Survival
of adults with acute lymphoblastic leukemia in Germany and the
United States. PLoS One. 9:e855542014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Inukai T: Mechanisms of drug resistance in
acute lymphoblastic leukemia. Rinsho Ketsueki. 57:2022–2028.
2016.(In Japanese). PubMed/NCBI
|
|
9
|
Nurse P: Wee beasties. Nature.
432:5572004. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Siripattarapravat K, Busta A, Steibel JP
and Cibelli J: Characterization and in vitro control of MPF
activity in zebrafish eggs. Zebrafish. 6:97–105. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Adhikari D and Liu K: The regulation of
maturation promoting factor during prophase I arrest and meiotic
entry in mammalian oocytes. Mol Cell Endocrinol. 382:480–487. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hirai H, Iwasawa Y, Okada M, Arai T,
Nishibata T, Kobayashi M, Kimura T, Kaneko N, Ohtani J, Yamanaka K,
et al: Small-molecule inhibition of Wee1 kinase by MK-1775
selectively sensitizes p53-deficient tumor cells to DNA-damaging
agents. Mol Cancer Ther. 8:2992–3000. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Creevey L, Ryan J, Harvey H, Bray IM,
Meehan M, Khan AR and Stallings RL: MicroRNA-497 increases
apoptosis in MYCN amplified neuroblastoma cells by targeting the
key cell cycle regulator WEE1. Mol Cancer. 12:232013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Mackintosh C, García-Domínguez DJ, Ordóñez
JL, Ginel-Picardo A, Smith PG, Sacristán MP and de Álava E: WEE1
accumulation and deregulation of S-phase proteins mediate MLN4924
potent inhibitory effect on Ewing sarcoma cells. Oncogene.
32:1441–1451. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sarcar B, Kahali S, Prabhu AH, Shumway SD,
Xu Y, Demuth T and Chinnaiyan P: Targeting radiation-induced G(2)
checkpoint activation with the Wee-1 inhibitor MK-1775 in
glioblastoma cell lines. Mol Cancer Ther. 10:2405–2414. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang G, Niu X, Zhang W, Caldwell JT,
Edwards H, Chen W, Taub JW, Zhao L and Ge Y: Synergistic antitumor
interactions between MK-1775 and panobinostat in preclinical models
of pancreatic cancer. Cancer Lett. 356:656–668. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Carrassa L, Chilà R, Lupi M, Ricci F,
Celenza C, Mazzoletti M, Broggini M and Damia G: Combined
inhibition of Chk1 and Wee1: In vitro synergistic effect
translates to tumor growth inhibition in vivo. Cell Cycle.
11:2507–2517. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ghiasi N, Habibagahi M, Rosli R, Ghaderi
A, Yusoff K, Hosseini A, Abdullah S and Jaberipour M: Tumour
suppressive effects of WEE1 gene silencing in breast cancer cells.
Asian Pac J Cancer Prev. 14:6605–6611. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kogiso T, Nagahara H, Hashimoto E,
Ariizumi S, Yamamoto M and Shiratori K: Efficient induction of
apoptosis by wee1 kinase inhibition in hepatocellular carcinoma
cells. PLoS One. 9:e1004952014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Porter CC, Kim J, Fosmire S, Gearheart CM,
van Linden A, Baturin D, Zaberezhnyy V, Patel PR, Gao D, Tan AC, et
al: Integrated genomic analyses identify WEE1 as a critical
mediator of cell fate and a novel therapeutic target in acute
myeloid leukemia. Leukemia. 26:1266–1276. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Qi W, Xie C, Li C, Caldwell JT, Edwards H,
Taub JW, Wang Y, Lin H and Ge Y: CHK1 plays a critical role in the
anti-leukemic activity of the wee1 inhibitor MK-1775 in acute
myeloid leukemia cells. J Hematol Oncol. 7:532014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tizzani A, Casetta G, Gontero P, Giammò A,
Ghabin H, Demurtas S and Pacchioni D: DNA flow cytometry and 67Ki
proliferating index as prognostic factors of early recurrence and
progression in G1-G2/Ta-T1 and G3/Ta-T1 transitional cell carcinoma
of the bladder. Minerva Urol Nefrol. 49:141–143. 1997.PubMed/NCBI
|
|
23
|
Wei Y, Mizzen CA, Cook RG, Gorovsky MA and
Allis CD: Phosphorylation of histone H3 at serine 10 is correlated
with chromosome condensation during mitosis and meiosis in
Tetrahymena. Proc Natl Acad Sci USA. 95:7480–7484. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Mateo J, Boysen G, Barbieri CE, Bryant HE,
Castro E, Nelson PS, Olmos D, Pritchard CC, Rubin MA and de Bono
JS: DNA repair in prostate cancer: Biology and clinical
implications. Eur Urol. 71:417–425. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Shang X, Shiono Y, Fujita Y, Oka S and
Yamazaki Y: Synergistic enhancement of apoptosis by DNA- and
cytoskeleton-damaging agents: A basis for combination chemotherapy
of cancer. Anticancer Res. 21:2585–2589. 2001.PubMed/NCBI
|
|
26
|
Carr AM, Green MH and Lehmann AR:
Checkpoint policing by p53. Nature. 359:486–487. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Xie G, Habbersett RC, Jia Y, Peterson SR,
Lehnert BE, Bradbury EM and D'Anna JA: Requirements for p53 and the
ATM gene product in the regulation of G1/S and S phase checkpoints.
Oncogene. 16:721–736. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hamzehloie T, Mojarrad M, Hasanzadeh
Nazarabadi M and Shekouhi S: The role of tumor protein 53 mutations
in common human cancers and targeting the murine double minute
2-p53 interaction for cancer therapy. Iran J Med Sci. 37:3–8.
2012.PubMed/NCBI
|
|
29
|
McGowan CH and Russell P: Cell cycle
regulation of human WEE1. EMBO J. 14:2166–2175. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Garcia K, Stumpff J, Duncan T and Su TT:
Tyrosines in the kinesin-5 head domain are necessary for
phosphorylation by Wee1 and for mitotic spindle integrity. Curr
Biol. 19:1670–1676. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Cornago M, Garcia-Alberich C,
Blasco-Angulo N, Vall-Llaura N, Nager M, Herreros J, Comella JX,
Sanchis D and Llovera M: Histone deacetylase inhibitors promote
glioma cell death by G2 checkpoint abrogation leading to mitotic
catastrophe. Cell Death Dis. 5:e14352014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
De Witt Hamer PC, Mir SE, Noske D, Van
Noorden CJ and Würdinger T: WEE1 kinase targeting combined with
DNA-damaging cancer therapy catalyzes mitotic catastrophe. Clin
Cancer Res. 17:4200–4207. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Aarts M, Sharpe R, Garcia-Murillas I,
Gevensleben H, Hurd MS, Shumway SD, Toniatti C, Ashworth A and
Turner NC: Forced mitotic entry of S-phase cells as a therapeutic
strategy induced by inhibition of WEE1. Cancer Discov. 2:524–539.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Heale JT, Ball AR Jr, Schmiesing JA, Kim
JS, Kong X, Zhou S, Hudson DF, Earnshaw WC and Yokomori K:
Condensin I interacts with the PARP-1-XRCC1 complex and functions
in DNA single-strand break repair. Mol Cell. 21:837–848. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Bharti AC, Takada Y and Aggarwal BB: PARP
cleavage and caspase activity to assess chemosensitivity. Methods
Mol Med. 111:69–78. 2005.PubMed/NCBI
|
|
36
|
Cruet-Hennequart S, Prendergast ÁM, Shaw
G, Barry FP and Carty MP: Doxorubicin induces the DNA damage
response in cultured human mesenchymal stem cells. Int J Hematol.
96:649–656. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Kreahling JM, Foroutan P, Reed D, Martinez
G, Razabdouski T, Bui MM, Raghavan M, Letson D, Gillies RJ and
Altiok S: Wee1 inhibition by MK-1775 leads to tumor inhibition and
enhances efficacy of gemcitabine in human sarcomas. PLoS One.
8:e575232013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kreahling JM, Gemmer JY, Reed D, Letson D,
Bui M and Altiok S: MK1775, a selective Wee1 inhibitor, shows
single-agent antitumor activity against sarcoma cells. Mol Cancer
Ther. 11:174–182. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Mir SE, De Witt Hamer PC, Krawczyk PM,
Balaj L, Claes A, Niers JM, Van Tilborg AA, Zwinderman AH, Geerts
D, Kaspers GJ, et al: In silico analysis of kinase expression
identifies WEE1 as a gatekeeper against mitotic catastrophe in
glioblastoma. Cancer Cell. 18:244–257. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Posthuma DeBoer J, Würdinger T, Graat HC,
van Beusechem VW, Helder MN, van Royen BJ and Kaspers GJ: WEE1
inhibition sensitizes osteosarcoma to radiotherapy. BMC Cancer.
11:1562011. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Nwabo Kamdje AH and Krampera M: Notch
signaling in acute lymphoblastic leukemia: Any role for stromal
microenvironment? Blood. 118:6506–6514. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Penton AL, Leonard LD and Spinner NB:
Notch signaling in human development and disease. Semin Cell Dev
Biol. 23:450–457. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Weng AP, Ferrando AA, Lee W, Morris JP IV,
Silverman LB, Sanchez-Irizarry C, Blacklow SC, Look AT and Aster
JC: Activating mutations of NOTCH1 in human T cell acute
lymphoblastic leukemia. Science. 306:269–271. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Yin C, Ye J, Zou J, Lu T, Du Y, Liu Z, Fan
R, Lu F, Li P, Ma D, et al: Role of stromal cells-mediated Notch-1
in the invasion of T-ALL cells. Exp Cell Res. 332:39–46. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Herranz D, Ambesi-Impiombato A, Palomero
T, Schnell SA, Belver L, Wendorff AA, Xu L, Castillo-Martin M,
Llobet-Navás D, Cordon-Cardo C, et al: A NOTCH1-driven MYC enhancer
promotes T cell development, transformation and acute lymphoblastic
leukemia. Nat Med. 20:1130–1137. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Zou J, Li P, Lu F, Liu N, Dai J, Ye J, Qu
X, Sun X, Ma D, Park J, et al: Notch1 is required for
hypoxia-induced proliferation, invasion and chemoresistance of
T-cell acute lymphoblastic leukemia cells. J Hematol Oncol.
6:32013. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Nwabo Kamdje AH, Mosna F, Bifari F, Lisi
V, Bassi G, Malpeli G, Ricciardi M, Perbellini O, Scupoli MT,
Pizzolo G, et al: Notch-3 and Notch-4 signaling rescue from
apoptosis human B-ALL cells in contact with human bone
marrow-derived mesenchymal stromal cells. Blood. 118:380–389. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Itoh M, Fu L and Tohda S: NF-kappaB
activation induced by Notch ligand stimulation in acute myeloid
leukemia cells. Oncol Rep. 22:631–634. 2009.PubMed/NCBI
|
|
49
|
Baldoni S, Sportoletti P, Del Papa B,
Aureli P, Dorillo E, Rosati E, Ciurnelli R, Marconi P, Falzetti F
and Di Ianni M: NOTCH and NF-κB interplay in chronic lymphocytic
leukemia is independent of genetic lesion. Int J Hematol.
98:153–157. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Chan SM, Weng AP, Tibshirani R, Aster JC
and Utz PJ: Notch signals positively regulate activity of the mTOR
pathway in T-cell acute lymphoblastic leukemia. Blood. 110:278–286.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Wang Z, Li Y, Banerjee S, Kong D, Ahmad A,
Nogueira V, Hay N and Sarkar FH: Down-regulation of Notch-1 and
Jagged-1 inhibits prostate cancer cell growth, migration and
invasion and induces apoptosis via inactivation of Akt, mTOR and
NF-kappaB signaling pathways. J Cell Biochem. 109:726–736.
2010.PubMed/NCBI
|
